Aclaris: Fourth Quarter Financial Overview

Aclaris Therapeutics Reports Fourth Quarter Financial Results

Aclaris Therapeutics Inc., based in Wayne, Pennsylvania, announced a net loss of $19.8 million for the fourth quarter.

This translates to a loss of 16 cents per share for the period.

The company’s performance fell short of analyst predictions. According to Zacks Investment Research, five analysts had anticipated a loss of 15 cents per share.

During the quarter, Aclaris generated $1.3 million in revenue, which was below the $1.9 million forecasted by analysts surveyed by Zacks.

At the close of trading, Aclaris shares were priced at $3.31, compared to $2.06 at the same time last year.